Pediatric neuro-oncology: current status and future directions
- PMID: 22897924
- DOI: 10.1111/j.1743-7563.2012.01558.x
Pediatric neuro-oncology: current status and future directions
Abstract
Tumors of the central nervous system (CNS) are the most common solid malignancies in childhood and are the leading cause of cancer-related death in this age group. While an ongoing improvement in overall prognosis has been achieved in the last few decades, current therapeutic approaches still confer significant morbidities, especially for the very young. The traditional strategies of surgery, radiotherapy and conventional cytotoxic chemotherapy need to be further refined while newer approaches, including molecularly targeted agents, hold the promise of better responses, improved outcomes and reduced toxicities. This article discusses treatment standards, the focus of current clinical investigations and the future promise of novel, biologically based approaches for the most common pediatric CNS tumors: primitive neuroectodermal tumors including medulloblastomas, ependymomas and astrocytomas (both low-grade and high-grade glioma).
© 2012 Wiley Publishing Asia Pty Ltd.
Similar articles
-
Pediatric CNS tumors: current treatment and future directions.Expert Rev Neurother. 2007 Aug;7(8):1029-42. doi: 10.1586/14737175.7.8.1029. Expert Rev Neurother. 2007. PMID: 17678498 Review.
-
State of the art chemotherapeutic management of pediatric brain tumors.Expert Rev Neurother. 2006 May;6(5):765-79. doi: 10.1586/14737175.6.5.765. Expert Rev Neurother. 2006. PMID: 16734524 Review.
-
Multidisciplinary management of childhood brain tumors: a review of outcomes, recent advances, and challenges.J Neurosurg Pediatr. 2011 Aug;8(2):135-48. doi: 10.3171/2011.5.PEDS1178. J Neurosurg Pediatr. 2011. PMID: 21806354 Review.
-
Treatments for astrocytic tumors in children: current and emerging strategies.Paediatr Drugs. 2006;8(3):167-78. doi: 10.2165/00148581-200608030-00003. Paediatr Drugs. 2006. PMID: 16774296 Review.
-
Advances in the management of pediatric central nervous system tumors.Ann N Y Acad Sci. 2008 Sep;1138:22-31. doi: 10.1196/annals.1414.005. Ann N Y Acad Sci. 2008. PMID: 18837879 Review.
Cited by
-
Impact of proton therapy on the DNA damage induction and repair in hematopoietic stem and progenitor cells.Sci Rep. 2023 Oct 9;13(1):16995. doi: 10.1038/s41598-023-42362-0. Sci Rep. 2023. PMID: 37813904 Free PMC article.
-
Causes of death in pediatric neuro-oncology: the sickkids experience from 2000 to 2017.J Neurooncol. 2020 Aug;149(1):181-189. doi: 10.1007/s11060-020-03590-w. Epub 2020 Aug 14. J Neurooncol. 2020. PMID: 32803658
-
Future clinical potential of oncolytic virotherapy for pediatric CNS tumors.CNS Oncol. 2013 Jul;2(4):307-10. doi: 10.2217/cns.13.25. CNS Oncol. 2013. PMID: 25054575 Free PMC article. No abstract available.
-
Targeted therapy in pediatric low-grade glioma.Curr Neurol Neurosci Rep. 2014 Apr;14(4):441. doi: 10.1007/s11910-014-0441-0. Curr Neurol Neurosci Rep. 2014. PMID: 24604059 Review.
-
Microrna expression signatures predict patient progression and disease outcome in pediatric embryonal central nervous system neoplasms.J Hematol Oncol. 2014 Dec 31;7:96. doi: 10.1186/s13045-014-0096-y. J Hematol Oncol. 2014. PMID: 25551588 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
